

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**KELUN-BIOTECH**  
**科伦博泰**

**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**

**四川科倫博泰生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6990)**

## **INSIDE INFORMATION**

### **GRANT OF LISTING APPROVAL BY THE STOCK EXCHANGE FOR THE H SHARE FULL CIRCULATION BY THE COMPANY**

This announcement is made by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated October 23, 2023, November 3, 2023 and November 14, 2023 (the “**Announcements**”) in relation to the proposed implementation of the H Share Full Circulation of certain domestic shares and unlisted foreign shares of the Company. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

#### **LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE**

The Company has applied to the Stock Exchange for the approval (the “**Listing Approval**”) of the listing of and the permission to deal in 62,567,234 H Shares (the “**Converted H Shares**”), representing the total number of domestic shares and unlisted foreign shares of the Company to be converted under the Conversion and Listing. The Board is pleased to announce that the Listing Approval was granted by the Stock Exchange on November 16, 2023.

#### **SHARE CAPITAL UPON COMPLETION OF THE CONVERSION AND LISTING**

The Conversion and Listing will involve a total of five Participating Shareholders holding an aggregate of 62,567,234 domestic shares and unlisted foreign shares of the Company, which represents approximately 28.54% of the total share capital of the Company upon completion of the Conversion and Listing, details of which are set out below:

<b>Participating Shareholder</b>	<b>Number of Converted H Shares</b>	<b>Approximate percentage of the Company's total share capital upon completion of the Conversion and Listing</b>
<i>Holders of Domestic Shares:</i>		
Sichuan Kelun Pharmaceutical Co., Ltd. (四川科倫藥業股份有限公司)	57,777,843	26.36%
Future Industry Investment Fund Phase II (Limited Partnership) (先進製造產業投資基金二期(有限合夥))	3,572,089	1.63%
Anling Weijian Equity Investment (Zibo) Limited Partnership (安齡偉健股權投資(淄博)合夥企業(有限合夥))	967,088	0.44%
Zhuhai Liangheng Equity Investment Partnership (Limited Partnership) (珠海良恒股權投資合夥企業(有限合夥))	115,778	0.05%
<i>Holder of Unlisted Foreign Shares:</i>		
Gygnus Real Company Limited	134,436	0.06%
<b>Total</b>	<b><u>62,567,234</u></b>	<b><u>28.54%</u></b>

Upon completion of the Conversion and Listing, the share capital structure of the Company will be as follows:

<b>Class of shares</b>	<b>As at the date of this announcement</b>		<b>Upon completion of the Conversion and Listing</b>	
	<i>Number of shares</i>	<i>Approximate percentage</i>	<i>Number of shares</i>	<i>Approximate percentage</i>
Domestic Shares	149,589,850	68.24%	87,157,052	39.76%
Unlisted Foreign Shares	5,548,478	2.53%	5,414,042	2.47%
H Shares	64,057,171	29.22%	126,624,405	57.77%
<b>Total</b>	<b><u>219,195,499</u></b>	<b><u>100.00%</u></b>	<b><u>219,195,499</u></b>	<b><u>100.00%</u></b>

The Company shall complete the relevant conversion and trading procedures in respect of the Converted H Shares and will make further announcement(s) on the progress of the Conversion and Listing in accordance with the Inside Information Provisions and/or the requirements of the Listing Rules.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**LIU Gexin**  
*Chairman of the Board and Non-executive Director*

Hong Kong, November 17, 2023

*As at the date of this announcement, the Board comprises Mr. LIU Gexin as the chairman of the Board and non-executive Director, Dr. GE Junyou and Dr. WANG Jingyi as executive Directors, Mr. LIU Sichuan, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive Directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping and Dr. LI Yuedong as independent non-executive Directors.*